Lilly to Present Results from Pivotal Breast Cancer Study of Abemaciclib and New Portfolio Data at ASCO 2017

PR Newswire — May 17, 2017

INDIANAPOLIS, May 17, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY)
today announced that new research demonstrating advances in the Company’s
oncology pipeline and product portfolio will be presented at the 53rd Annual
Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June
2-6, 2017. Data underscore a strategic focus on targeting the biology of cancer
to find new ways to fight cancer and transform care for patients. Highlights
include oral presentation of Phase 3 data for abemaciclib, an investigational
cyclin-dependent kinase (CDK)4 & 6 inhibitor for breast cancer, as well as new
data from the Company’s ongoing immuno-oncology clinical collaborations with
Merck (known as MSD outside the U.S. and Canada) in two trials that are
evaluating pemetrexed-plus-carboplatin and ramucirumab, respectively, in
combination with Merck’s pembrolizumab.

“We are pleased to share how we are building foundational therapeutics with the
goal of delivering medicines that help people with cancer live longer and
healthier lives,” said Levi Garraway, M.D., Ph.D., senior vice president, global
development and medical affairs, Lilly Oncology. “We are particularly excited
about the latest results from the abemaciclib MONARCH clinical development
program, in which we have endeavored to raise the bar with a potential
next-generation CDK4 & 6 inhibitor that we believe may improve outcomes for
patients living with breast cancer.”

“With abemaciclib we hoped to develop an oral CDK4 & 6 inhibitor that could be
taken without interruption. In preclinical research, continued disruption was
shown to stop tumor cells from entering the cell cycle, which prevents tumor
cell growth and, ultimately, promotes tumor cell death that may translate into
clinical benefit for breast cancer patients,” said Alfonso de Dios, senior
research fellow, discovery chemistry research & technologies, Lilly.

Abemaciclib Data at ASCO
Detailed data from the Phase 3 MONARCH 2 study, which evaluated abemaciclib in
combination with fulvestrant in women with hormone-receptor-positive (HR+),
human epidermal growth factor receptor 2-negative (HER2-) advanced breast
cancer, will be presented in an oral presentation. The intent-to-treat
population of 669 patients in MONARCH 2 had experienced disease progression on
or within 12 months of receiving endocrine treatment in the neoadjuvant or
adjuvant setting or while receiving first-line endocrine therapy for metastatic
disease.

Additionally, abemaciclib has been shown in preclinical and Phase 1 studies to
cross the blood-brain barrier, making this an area of interest for further
study. This year’s meeting will allow Lilly to share preliminary Phase 2 data
evaluating a CDK4 & 6 inhibitor in patients with new or progressive brain
metastases secondary to advanced breast cancer, lung cancer or melanoma.

Select studies, along with the times and locations of their data sessions, are
highlighted below.

Abemaciclib

— Abstract #1000: Oral Presentation: Breast Cancer–Metastatic: Saturday,
June 3, 2017; 1:15-4:15 p.m. CDT
o MONARCH 2: Abemaciclib in combination with fulvestrant in patients with
HR+/HER2- advanced breast cancer who progressed on endocrine therapy
o Author/Speaker: George W. Sledge, M.D., F.A.S.C.O., Stanford University
School of Medicine
o Location: Hall D1
— Abstract #1019: Breast Cancer–Metastatic: Sunday, June 4, 2017;
8:00-11:30 a.m. CDT
o Abemaciclib for the treatment of brain metastases (BM) secondary to
hormone-receptor-positive (HR+), HER2- breast cancer
o Author/Speaker: Sara M. Tolaney, M.D., M.P.H., Dana-Farber Cancer Institute
o Location: Hall A (Poster Board #11)
o Poster Discussion Session: Sunday, June 4, 2017; 4:45-6:00 p.m. CDT, Hall B1
— Abstract #TPS1109: Breast Cancer–Metastatic: Sunday, June 4, 2017;
8:00-11:30 a.m. CDT
o A Phase 2 randomized study to compare abemaciclib plus trastuzumab with or
without fulvestrant to standard of care chemotherapy plus trastuzumab in
hormone-receptor-positive, HER2-positive, advanced breast cancer (monarcHER)
o Author/Speaker: Sara M. Tolaney, M.D., M.P.H., Dana-Farber Cancer Institute
o Location: Hall A (Poster Board #99b)
— Abstract #TPS4150: Gastrointestinal (Noncolorectal) Cancer: Saturday,
June 3, 2017; 8:00-11:30 a.m. CDT
o A Phase 2 study of abemaciclib as a monotherapy and in combination with
other agents in patients with previously treated metastatic pancreatic
ductal adenocarcinoma (PDAC)
o Author/Speaker: E. Gabriela Chiorean, M.D., Fred Hutchinson Cancer Research
Center
o Location: Hall A (Poster Board #132b)
Fruquintinib

— Abstract #3508: Oral Presentation: Gastrointestinal (Colorectal) Cancer:
Monday, June 5, 2017; 3:00-6:00 p.m. CDT
o A randomized, double-blind, placebo-controlled, multi-centered Phase 3 trial
comparing fruquintinib versus placebo plus best supportive care in Chinese
patients with metastatic colorectal cancer (FRESCO)
o Author/Speaker: Jin Li, M.D., Fudan University Shanghai Cancer Center,
Shanghai Medical College
o Location: Hall D2
Immuno-Oncology Collaborations with pemetrexed-plus-carboplatin or ramucirumab

— Abstract #9094: Lung Cancer–Non-Small Cell Metastatic: Saturday, June
3, 2017; 8:00-11:30 a.m. CDT
o First-line carboplatin and pemetrexed (CP) with or without pembrolizumab
(pembro) for advanced nonsquamous NSCLC: Updated results of KEYNOTE-021
cohort G
o Author/Speaker: Vassiliki Papadimitrakopoulou, M.D., The University of Texas
MD Anderson Cancer Center
o Location: Hall A (Poster Board #420)
— Abstract #4046: Gastrointestinal (Noncolorectal) Cancer: Saturday, June
3, 2017; 8:00-11:30 a.m. CDT
o Ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously
treated advanced gastric or gastroesophageal junction (G/GEJ)
adenocarcinoma: A multi-disease Phase 1 study
o Author/Speaker: Ian Chau, M.D., F.R.C.P, Royal Marsden Hospital
o Location: Hall A (Poster Board #38)
Olaratumab

— Abstract #TPS2599: Developmental Therapeutics–Clinical Pharmacology and
Experimental Therapeutics: Monday, June 5, 2017; 8:00-11:30 a.m. CDT
o A Phase 1, open-label, dose-escalation study of olaratumab as a single agent
and in combination with doxorubicin, vincristine/irinotecan, or high-dose
ifosfamide in pediatric patients with relapsed or refractory solid tumors
o Author/Speaker: Leo Mascarenhas, M.B.B.S., M.D., M.S., Children’s Center for
Cancer and Blood Diseases, Children’s Hospital Los Angeles, University of
Southern California
o Location: Hall A (Poster Board #89b)
Emibetuzumab

— Abstract #9019: Lung Cancer–Non-Small Cell Metastatic: Saturday, June
3, 2017; 8:00-11:30 a.m. CDT
o A randomized, controlled, open-label Phase 2 study of erlotinib (E) with or
without the MET antibody emibetuzumab (Emi) as first-line treatment for
EFGRmt non-small cell lung cancer (NSCLC) patients who have disease control
after an eight-week lead-in treatment with erlotinib
o Author/Speaker: Giorgio V. Scagliotti, M.D., Ph.D., Department of Oncology –
University of Torino
o Location: Hall A (Poster Board #345)
o Poster Discussion Session: Saturday, June 3, 2017; 3:00-4:15 p.m. CDT, Hall
D2
Galunisertib

— Abstract #4097: Gastrointestinal (Noncolorectal) Cancer: Saturday, June
3, 2017; 8:00-11:30 a.m. CDT
o A Phase 2 study of galunisertib (TGF-B R1 inhibitor) and sorafenib in
patients with advanced hepatocellular carcinoma (HCC)
o Author/Speaker: Robin Kate Kelley, M.D., University of California, San
Francisco
o Location: Hall A (Poster Board #89)
LY3023414

— Abstract #1064: Breast Cancer–Metastatic: Sunday, June 4, 2017;
8:00-11:30 a.m. CDT
o Safety and tolerability of the dual PI3K/mTOR inhibitor LY3023414 in
combination with fulvestrant in treatment refractory advanced breast cancer
patients
o Author/Speaker: Anna M. Varghese, M.D., Memorial Sloan-Kettering Cancer
Center
o Location: Hall A (Poster Board #56)
LY3009120

— Abstract #2507: Oral Presentation: Developmental Therapeutics–Clinical
Pharmacology and Experimental Therapeutics: Saturday, June 3, 2017;
1:15-4:15 p.m. CDT
o A first-in-human dose Phase 1 study of LY3009120 in advanced cancer patients
o Author/Speaker: David S. Hong, M.D., The University of Texas MD Anderson
Cancer Center
o Location: E450ab
LY3022855

— Abstract #2523: Developmental Therapeutics–Clinical Pharmacology and
Experimental Therapeutics: Monday, June 5, 2017; 8:00-11:30 a.m. CDT
o A Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor
(CSF-1R) inhibitor, in patients (pts) with advanced solid tumors
o Author/Speaker: Afshin Dowlati, M.D., University Hospitals Seidman Cancer
Center, Case Comprehensive Cancer Center, Case Western Reserve University
o Location: Hall A (Poster Board #15)
LY3039478

— Abstract #6024: Head and Neck Cancer: Monday, June 5, 2017; 1:15-4:45
p.m. CDT
o Notch pathway inhibition with LY3039478 in adenoid cystic carcinoma (ACC)
o Author/Speaker: Caroline Even, Institut Gustave Roussy
o Location: Hall A (Poster Board #12)
o Poster Discussion Session: Monday, June 5, 2017; 4:45-6:00 p.m. CDT, S406
Notes to Editor

About Lilly Oncology
For more than 50 years, Lilly has been dedicated to delivering life-changing
medicines and support to people living with cancer and those who care for them.
Lilly is determined to build on this heritage and continue making life better
for all those affected by cancer around the world. To learn more about Lilly’s
commitment to people with cancer, please visit www.LillyOncology.com.

About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make
life better for people around the world. We were founded more than a century ago
by a man committed to creating high-quality medicines that meet real needs, and
today we remain true to that mission in all our work. Across the globe, Lilly
employees work to discover and bring life-changing medicines to those who need
them, improve the understanding and management of disease and give back to
communities through philanthropy and volunteerism. To learn more about Lilly,
please visit us at www.lilly.com and www.lilly.com/newsroom/social-channels.
P-LLY

© Lilly USA, LLC 2017. ALL RIGHTS RESERVED.

Lilly Forward-Looking Statement
This press release contains “forward-looking statements” (as that term is
defined in the United States Private Securities Litigation Reform Act of 1995)
regarding Lilly’s oncology portfolio and pipeline, including abemaciclib,
emibetuzumab, fruquintinib, olaratumab, pemetrexed, ramucirumab, galunisertib,
LY3023414, LY3009120, LY3022855, and LY3039478. This press release reflects
Lilly’s current beliefs. However, there are substantial risks and uncertainties
in the process of drug research, development, and commercialization. Among other
risks, there can be no guarantee that these treatment options will receive
regulatory approval, or, if approved, that it will achieve intended benefits or
become a commercially successful product. For further discussion of these and
other risks and uncertainties that could cause actual results to differ
materially from Lilly’s expectations, please see the company’s latest Forms 10-K
and 10-Q filed with the U.S. Securities and Exchange Commission. Except as
required by law, Lilly undertakes no duty to update forward-looking statements.

Refer to: Erin Graves; graves_erin_elissa@lilly.com; 908-202-6354 (media)

Phil Johnson; johnson_philip_l@lilly.com; 317-655-6874 (investors)

To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/lilly-to-present-results-from-pivotal-breast-cancer-study-of-abemaciclib-and-new-portfolio-data-at-asco-2017-300459622.html

SOURCE Eli Lilly and Company

Subject Codes: PC/t.170517170006899, PT/lang.en, PC/ticker, IN/HEA,
IN/PHA, IN/MTC, IN/BIO, SU/TRI, SU/TDS, RE/Indiana,
PC/priority.r, PC/category.f, PC/DataFeat_indpr,
PC/DataFeat_natl3, PC/port_32, PC/class.1245,
PC/WAVO_….h., PC/APT_….h, PC/trade_h, PC/wavo5_h,
PC/class.1030, PC/WAVO_l….., PC/APT_l…., PC/state_l,
PC/wavo1_l, PC/class.1254, PC/WAVO_….q., PC/APT_….q,
PC/trade_q, PC/wavo5_q, PC/class.1000, PC/WAVO_..b…,
PC/APT_..b.., PC/circuit_b, PC/wavo3_b, PC/Billing_L85,
PC/Billing_RWB, PC/Billing_TNW, PC/Billing_US1,
PC/1stAcc_916319, PC/OtherAcc_916306, PC/OtherAcc_643307,
PC/bureau_DE, PC/port_01, PC/port_96, PC/port_31,
PC/port_19, PC/port_91, PC/photo, PC/id_DE93899

Company Codes: NYSE:LLY

Leave a Reply


Fatal error: Call to undefined function show_subscription_checkbox() in /home3/steer/public_html/indianapressreleases.com/wp-content/themes/comfy/comments.php on line 95